Results 51 to 60 of about 8,174 (197)

Evaluation of Patients' Recovery from Hepatitis C Following Antiviral Treatment with Daclatasvir and Sofosbuvir in AL-Baha Region [PDF]

International Journal of Advanced Humanities Research
The liver is the largest organ in the body, located below the diaphragm and protected by the lower ribs of the rib cage (Johns Hopkins Medicine, 2022).
Fahad Alghamdi, Rashed Mohammed
doaj   +1 more source

Recent advances in managing chronic HCV infection: Focus on therapy in patients with severe liver disease [PDF]

, 2016
Chronic hepatitis C virus (HCV) infection still represents a major public health problem, as it is thought to be responsible for more than 350,000 deaths around the globe on a yearly basis.
Maan, R. (Raoel), Meer, A.J.P. (Adriaan) van der   +1 more
core   +5 more sources

The Impact of Hepatitis C and Socio‐Demographic Variables on Health‐Related Quality of Life in Pakistan: Cross‐Sectional Study

Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.
ABSTRACT Approximately 8.8 million people are living with chronic hepatitis C virus (HCV) in Pakistan. We assessed factors related to health‐related quality of life (HRQoL) among the general population screened for HCV and calculated the national burden in quality‐adjusted life years (QALYs).
Siwaporn Niyomsri, Aaron G. Lim, Ambreen Arif, Muhammad Asim, Auj Chaudhry, Naheed Choudhry, Aliya Hasnain, Polychronis Kemos, Chris Metcalfe, Asad Choudhry, Saeed Sadiq Hamid, Saad Niaz, Huma Qureshi, Graham R. Foster, Peter Vickerman, Josephine G. Walker, HepFreePak team, Aqsa Ramzan, Atif Saghir, Ejaz Alam, Ghayas Hai, Mohd Saadullah, Muhammad Nabeel Shafqat, Muhammad Sufyan Tahir, Taha Khan   +24 more
wiley   +1 more source

DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIR

International Journal of Pharmacy & Integrated Health Sciences
Background: Sofosbuvir (SOF) and daclatasvir (DCV) are usually prescribed in combination for the treatment of hepatitis C worldwide. Objectives: In the present study a novel, simple, rapid, and cost-effective reversed-phase high performance liquid ...
Syed Hassan Murtaza, Ahmed Umer Sohaib Ahmed, Tassawer-e-Meran, Sonam Anees, Najam-ul-Hassan Khan, Kishwar Sultana   +5 more
doaj   +1 more source

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation [PDF]

, 2012
A recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) can lead to accelerated allograft injury and fibrosis. The aim of this article is to report the first ever use of daclatasvir (DCV; also known as BMS‐790052), a potent orally ...
Alcaide, Bacon, Berenguer, Berenguer, Bifano, Carrión, Chayama, Forman, Fridell, Gane, Gane, Garg, Guillouche, Hanouneh, Hézode, Jacobson, Kugelmas, Lai, Lee, Levitsky, Levitsky, Lok, Machicao, Naoum, Narang, Nettles, Pelletier, Picciotto, Poordad, Prieto, Schluger, Selzner, Sharma, Sharma, Sheiner, Sulkowski, Suzuki, Suzuki, Veldt, Verna, Weston, Zeuzem   +41 more
core   +1 more source

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals [PDF]

, 2017
In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because ...
Caputo, Mariela, Corach, Daniel, Flichman, Diego Martin, Hulaniuk, María L., Trinks, Julieta   +4 more
core   +1 more source

Conformational Trajectory of the Molecular Chameleon Grazoprevir From Formulation to Target‐Bound

Chemistry – A European Journal, Volume 32, Issue 8, 23 February 2026.
ABSTRACT Macrocycles represent a promising class of beyond‐rule‐of‐5 (bRo5) therapeutics, capable of targeting proteins traditionally considered undruggable by conventional small molecules. Macrocycles exhibit intrinsic flexibility and often display a “chameleon‐like” ability to adapt to their environment, thereby enhancing their oral bioavailability ...
Lianne H. E. Wieske, Guanhong Bu, Máté Erdélyi, Jan Kihlberg, Tamir Gonen, Emma Rova Danelius   +5 more
wiley   +1 more source

Assessment of auditory function in hepatitis “C” patients managed by combination of sofosbuvir and daclatsavir

The Egyptian Journal of Otolaryngology, 2022
Background To evaluate the effect of daclatasvir and sofosbuvir on auditory function in hepatitis C patients. Thirty hepatitis C virus (HCV) patients were included in this study with age ranged from 22 to 55 years.
El-Zahraa M. Meghezel, Mohammed A. Abd Al-Ghaffar, Asmaa Naser Mohammad, Samar M. Mahmoud, Usama M. Abdelaal, Salwa Mourad   +5 more
doaj   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters

The Journal of Clinical Pharmacology, Volume 66, Issue 2, February 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug candidate for the treatment of chronic hepatitis C virus infection. Potential drug–drug interactions (DDIs) of bemnifosbuvir as a substrate or perpetrator with regard to ATP‐binding cassette (ABC) and solute carrier (SLC) transporters were evaluated in vitro and in clinical studies ...
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Nancy Agrawal, Janet Hammond   +9 more
wiley   +1 more source